Search
-
Evaluating and adapting your soon-to-launch pharma strategy
Covid-19 has greatly disrupted the channels of communication between healthcare professionals and pharma manufacturers, especially those preparing for a product launch.
-
Assessing the risk profile of recently launched drugs
Manufacturers of the 48 launched products since January 2019 are facing a unique challenge in the current Covid-19 market.
-
Signals #4: Understanding the coronavirus crisis
This fourth edition sees us bring together our latest research on coronavirus and draws on our surveys, social media monitoring and the analysis of our teams around the world.
-
Multi-source healthcare data
The world of pharma business insight is likely to change as it embraces a multi-data source reality.
-
Evolution of prostate cancer treatment gathers speed
What are the treatment options for this too-prevalent disease? And the outlook for the future as clinical outcomes evolve?
-
The world after
The Covid-19 epidemic has magnified the extreme fragility of the French healthcare system, facing unequaled demand for care and ending up almost bled dry. Preserving its mission implies a real transformation.
-
Signals #3: Understanding the coronavirus crisis
The third edition of our digest brings together Ipsos’ latest research on coronavirus and draws on our surveys, social media monitoring and analysis from our teams around the world.
-
ARF: How Covid-19 is affecting public attitudes [Webinar recording]
Every crisis is unique, but every crisis also has antecedents in history – especially with regard to the crisis’s effect on public opinion.
-
What the pharma sales force needs to know about how COVID-19 is impacting HCP practices [Webinar recording]
Watch our on-demand webinar and listen as Ipsos’ experts review the first-wave results of our new regular COVID-19 HCP Surveillance Research of 300+ HCPs across seven specialties.
-
Medical Devices & Diagnostics Pulse Survey: Diabetes
Check out the latest results from our Medical Devices & Diagnostics Pulse Survey, focusing on Diabetes – with results benchmarked to 2018.